RIGI and breast cancer: Consistent with these observations, a previous study demonstrated that the active metabolite of tamoxifen (TAM), 4-hydroxytamoxifen (4-OH-TAM), regulates the expression of multiple genes, including the upregulation of DDX58 in estrogen receptor-positive (ER+) breast cancer MCF-7 cells.